Clinical trial NCT05687864: Study of Polyglycan Superparamagnetic Ferric Oxide Injection on Cardiovascular Magnetic Resonance Imaging
Official title: Single-center, Multiple-strength, Single-dose Phase I Clinical Trial to Evaluate the Effect of Polyglycan Superparamagnetic Ferric Oxide Injection on Cardiovascular Magnetic Resonance Imaging in Patients With Chronic Kidney Disease
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: PHASE1
Conditions: Magnetic Resonance Imaging
Chronic Kidney Diseases
Lead sponsor: Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Sponsor class: INDUSTRY
First posted: 2023-01-18
Enrollment: 30
Sex: ALL
Minimum age (years): 18
Maximum age (years): 75
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: DIAGNOSTIC

Brief summary: Polysaccharide super paramagnetic ferric oxide injection is an iron supplement developed for patients with iron deficiency anemia. Due to its characteristics, it has the potential to be a contrast agent. The DJTCSCYHT-I-04 study is a single-center, multiple-strength and single-dose phase I clinical study on cardiovascular MRI in patients with chronic kidney disease, aiming to investigate the effects and safety of multi-strength, single-dose at different time points, and to provide reference for clinical diagnosis and MRI enhancement.


Eligibility criteria: Inclusion Criteria:

* The subjects voluntarily joined the study, signed the informed consent, and the compliance was good.;
* Age: ≥18 years old (at the time of signing the informed consent), gender is not limited;
* Patients diagnosed with Chronic Kidney Disease (CKD, 2012 KDIGO Guidelines);
* Eastern Cooperative Oncology Group (ECOG) score 0\~1; Expected survival ≥3 months;
* Serum ferritin ≤ 1000μg/L and transferrin saturation ≤ 50%;
* The major organs function are good and meet the following criteria:

  1. blood routine examination:

     1. Hemoglobin ≥ 90g/L
     2. Neutrophil count (NEUT) ≥1.5×109/L;
     3. Platelet count (PLT) ≥ 75×109/L;
  2. Biochemical examination should meet the following standards:

     1. Total bilirubin (TBIL) ≤ 1.5 times the upper limit of normal (ULN);
     2. Alanine transferase (ALT), aspartate transferase (AST) and gamma glutamyltransferase (gamma-GGT) ≤ 3ULN;
  3. Left ventricular ejection fraction (LVEF) ≥50%.
* Women of reproductive age should agree to use effective birth control during the study period and for 6 months after the study, and have a negative serum-pregnancy test within 7 days prior to study enrollment; Men should agree that effective birth control must be used during the study period and for six months after the end of the study period.

Exclusion Criteria:

* Had or currently have malignant tumors within 3 years. The following three conditions were eligible for inclusion:

  1. patients with other malignancies treated with a single operation achieved continuous 5-year disease-free survival (DFS);
  2. Cured cervical carcinoma in situ, non-melanoma skin cancer, and superficial bladder tumors \[Ta (non-invasive tumor), Tis (carcinoma in situ), and T1 (tumor infiltrating basal membrane)\];
  3. The disease was stable as assessed by the investigators, and the concomitant drugs did not affect medication during the trial and follow-up period.
* Subjects with any severe and/or uncontrolled medical conditions, including:

  1. Poorly controlled hypertension (systolic blood pressure ≥150mmHg or diastolic blood pressure ≥100 mmHg) or poorly controlled hypotension (systolic blood pressure \<90mmHg or diastolic blood pressure \<60 mmHg);
  2. Have ≥ grade 2 myocardial ischemia or myocardial infarction and/or severe or malignant arrhythmias \[including QTc ≥450ms in men, QTc ≥470ms in women\] and/or ≥ grade 2 congestive heart failure \[New York Heart Association (NYHA)\];
  3. Active infection (≥NCI, CTC AE 5.0, Grade 2);
  4. Viral hepatitis, syphilis, HIV and other infectious diseases;
  5. A history of immunodeficiency, including acquired or congenital immunodeficiency diseases, or a history of organ transplantation;
  6. People who have epilepsy and require treatment.
* Research and treatment related:

  1. Patients with iron deficiency anemia;
  2. Subjects who are allergic to intravenous iron preparations, the investigational drug or any of its components, or two or more types of drugs;
  3. Subjects who plan to undergo magnetic resonance imaging during the study period and during follow-up.
* Participants who have participated in other clinical trials of drugs or medical device within 28 days before the start of the study treatment;
* Those who have a history of psychotropic drug abuse and cannot abstain or have mental disorders;
* Pregnant or lactating women;
* Patients with non-magnetic compatible metal foreign bodies (false teeth, contraceptive rings, metal implants, metal clips, etc.) and claustrophobia; Patients with difficulty or inability to tolerate MRI scanning;
* Subjects with concomitant diseases that, in the investigator's judgment, seriously endanger subjects' safety or interfere with the completion of the study, or who are deemed unsuitable for enrollment for other reasons.

Primary outcomes:
measure: Signal-to-Noise Ratio (SNR)
timeFrame: Before administration, 5minutes, 24 hours, 48 hours after administration
measure: Contrast to noise ratio (CNR)
timeFrame: Before administration, 5minutes, 24 hours, 48 hours after administration
measure: Image quality score before administration
timeFrame: Before administration
measure: Image quality score at 5 minutes
timeFrame: 5 minutes after administration
measure: Image quality score at 24 hours
timeFrame: 24 hours after administration
measure: Image quality score at 48 hours
timeFrame: 48 hours after administration
Secondary outcomes:
measure: T2* value of Liver
timeFrame: Before administration, and day 28, day 60, day 90 after administration
measure: R2 value of Liver
timeFrame: Before administration, and day 28, day 60, day 90 after administration
measure: Magnetic sensitivity of brain tissue
timeFrame: Before administration, and day 28, day 60, day 90 after administration
measure: Incidence of adverse events
timeFrame: From the enrollment of the subjects to 90 days after administration
measure: Incidence of severe adverse events
timeFrame: From the enrollment of the subjects to 90 days after administration
Other outcomes:
Locations:
city: Beijing
country: China
facility: Beijing Chaoyang Hospital, Capital Medical University
state: Beijing
Study officials:
References: